Patents Assigned to DEVELOPMENT FOUNDATION
  • Management and recovery of distributed storage of replicas
    Patent number: 9535802
    Abstract: A method of data replica recovery that is based on separate storage drives connected to a network where each storage drive has a storage space divided to contiguous storage segments and is electronically connected to a memory support component via a connection. Pairs of replicas, each of one of a plurality of data units, are stored in a manner that allows, in response to detection of a storage failure in one storage drive, to create replacement replicas in the memory support components of the other storage drives to assure that two replicas of each data unit can be found in the storage system.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: January 3, 2017
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Dan Tsafrir, Eitan Rosenfeld
  • METHODS AND COMPOSITIONS RELATING TO IMPROVED LENTIVIRAL VECTORS AND THEIR APPLICATIONS
    Publication number: 20160375152
    Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Applicant: Research Development Foundation
    Inventors: Didier TRONO, Patrick SALMON
  • UROCORTIN-III AND USES THEREOF
    Publication number: 20160375102
    Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to b e identified receptor.
    Type: Application
    Filed: July 8, 2016
    Publication date: December 29, 2016
    Applicant: Research Development Foundation
    Inventors: Wylie W. VALE, JR., Kathy A. LEWIS, Marilyn H. PERRIN, Koichi KUNITAKE, Jean E. F. RIVIER, Jozsef GULYAS
  • Breath analysis of pulmonary nodules
    Patent number: 9528979
    Abstract: The present invention provides a unique profile of volatile organic compounds as breath biomarkers for lung cancer. The present invention further provides the diagnosis, prognosis and monitoring of lung cancer or predicting the response to an anti-cancer treatment through the detection of the unique profile of volatile organic compounds indicative of lung cancer at its various stages.
    Type: Grant
    Filed: November 15, 2012
    Date of Patent: December 27, 2016
    Assignees: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD., TEL HASHOMER MEDICAL RESEARCH, INFRASTRUCTURE AND SERVICES LTD.
    Inventors: Hossam Haick, Nir Peled
  • Ion sensitive detector
    Patent number: 9518953
    Abstract: An ISFET detector for determining concentration of a target ion in a fluid, the apparatus comprising: a semiconducting substrate comprising a source and a drain having source and drain electrodes respectively and a channel region between them in the substrate; an insulating material overlying the channel region; a gate electrode formed on the insulating material; a reference electrode electrifiable to establish an electric field in the channel region; an accumulator comprising a layer of material of thickness less than or equal to about 2 nm (nanometers) that accumulates a quantity of target ions responsive to concentration of the target ions in the fluid; a layer of a conducting material on which the accumulator is formed that is separate from the gate electrode; and a conducting element that electrically connects the layer of conducting material to the gate electrode.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: December 13, 2016
    Assignee: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.
    Inventors: Yael Nemirovsky, Lior Gal, Igor Brouk
  • Stent for restenosis prevention
    Patent number: 9510959
    Abstract: A device for use in reducing or preventing the occurrence of restenosis following procedures such as PTCA, in which a stent is used to hold a bodily lumen open. The device comprises a two layered stent, one lying within the other. Both stent layers have an open weave structure, such that they can expand to the correct dimensions after implantation. The outer stent layer is static and grips the inner wall of the lumen in which it is deployed in the usual manner. The inner layer stent is constructed such that it can be vibrated relative to the outer static stent layer. The inner layer stent may be made of a material which can be vibrated from an external source, such as a ferromagnetic material. This vibration prevents restenosis of the treated lumen. Alternatively, a vibrator, such as a piezoelectric device, can be installed on the inner stent layer.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: December 6, 2016
    Assignee: Technion Research & Development Foundation Ltd.
    Inventors: Moshe Shoham, Amit Reches, Lucy Leshansky, Michael Groskop, Shachar Millis, Yishai Pentanovich
  • RTEF-1 variants and the use thereof for inhibition of angiogenesis
    Patent number: 9512423
    Abstract: Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: December 6, 2016
    Assignee: Research Development Foundation
    Inventors: J. Timothy Stout, Trevor J. McFarland, Binoy Appukuttan
  • Dielectric metasurface optical elements
    Patent number: 9507064
    Abstract: A dielectric gradient metasurface optical device provides optical wavefront shaping using an ultrathin (less than 100 nm thick) layer of nanoscale geometric Pancharatnam-Berry phase optical elements deposited on a substrate layer. The optical elements are nanobeams composed of high refractive index dielectric material. The nanobeams have uniform size and shape and are arranged with less than 200 nm separations and spatially varying orientations in the plane of the device such that the optical device has a spatially varying optical phase response capable of optical wavefront shaping. The high refractive index dielectric material may be materials compatible with semiconductor electronic fabrication, including silicon, polysilicon, germanium, gallium arsenide, titanium dioxide, or iron oxide.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: November 29, 2016
    Assignees: The Board of Trustees of the Leland Stanford Junior University, TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LIMITED
    Inventors: Mark L. Brongersma, Dianmin Lin, Pengyu Fan, Erez Hasman
  • Receiver, transmitter and a method for digital multiple sub-band processing
    Patent number: 9503284
    Abstract: Highly efficient digital domain sub-band based receivers and transmitters.
    Type: Grant
    Filed: June 10, 2012
    Date of Patent: November 22, 2016
    Assignee: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.
    Inventors: Moshe Nazarathy, Alex Tolmachev
  • Serine protease molecules and therapies
    Patent number: 9499807
    Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: November 22, 2016
    Assignee: Research Development Foundation
    Inventors: Michael G. Rosenblum, Khalid Amanali Mohamedali, Lawrence H. Cheung
  • METHODS AND COMPOSITIONS FOR MODULATION OF OLFML3 MEDIATED ANGIOGENESIS
    Publication number: 20160333084
    Abstract: The present invention relates to antibodies against specific domains of Olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the Olfml3 antagonists.
    Type: Application
    Filed: August 3, 2016
    Publication date: November 17, 2016
    Applicant: Research Development Foundation
    Inventors: Beat A. IMHOF, Marijana MILJKOVIC-LICINA, Philippe HAMMEL
  • Polymer-conjugated albumin hydrogels for controlled release of therapeutic agents
    Patent number: 9492376
    Abstract: A hydrogel system comprising polymer-conjugated albumin molecules is provided for controlled release delivery of therapeutic agents. The polymer is a functionalized synthetic polymer, preferably PEG-diacrylate. The polymer-conjugated albumin is preferably mono-PEGylated albumin. The hydrogel system may comprise a matrix to which the polymer-conjugated albumin molecules are linked via a functional group of the polymer. The matrix may be formed from the same polymer of the polymer-albumin conjugate.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: November 15, 2016
    Assignee: TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD.
    Inventors: Dror Seliktar, Liat Oss-Ronen
  • Diamond-coated substrates
    Patent number: 9487856
    Abstract: A composite structure, comprising a cemented carbide substrate (e.g., tungsten carbide substrate cemented with cobalt, such as WC—Co), a thin interlayer disposed over the substrate, and a contiguous diamond film disposed over the interlayer, as well as processes of preparing such a composite structure and uses thereof, are provided. The composite structure is characterized by at least one of a substrate binder concentration of at least 2 percents by weight, interlayer thickness less than 20 microns, a homogenous interlayer made substantially of crystalline chromium nitride, a low to null binder concentration in the interlayer, and a high co-adhesion of the diamond film to the interlayer and the interlayer to the substrate.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: November 8, 2016
    Assignee: Technion Research & Development Foundation Limited
    Inventor: Alon Hoffman
  • MEDIA FOR CULTURING STEM CELLS
    Publication number: 20160319241
    Abstract: Well-defined, xeno-free culture media which comprise a TGF-beta isoform or the chimera formed between IL6 and the soluble IL6 receptor (IL6RIL6), which are capable of maintaining stem cells, and particularly, human embryonic stem cells, in an undifferentiated state are provided. Also provided are cell cultures comprising the culture media and the stem cells and methods of expanding and deriving embryonic stem cells in such well-defined, xeno-free culture media. In addition, the present invention provides methods of differentiating ESCs or EBs formed therefrom for the generation of lineage specific cells.
    Type: Application
    Filed: July 14, 2016
    Publication date: November 3, 2016
    Applicant: Technion Research & Development Foundation Limited
    Inventors: Michal AMIT, Joseph ITSKOVITZ-ELDOR
  • Apparatus and methods for optical coherence tomography and two-photon luminescence imaging
    Patent number: 9482513
    Abstract: Exemplary embodiments of the present disclosure include a combined catheter-based optical coherence tomography-two-photon luminescence (OCT-TPL) imaging system. Exemplary embodiments further include methods to detect, and further characterize the distribution of cellular components (e.g., macrophage, collagen/elastin fiber, lipid droplet) in thin-cap fibroatheromas with high spatial resolution in vivo.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 1, 2016
    Assignee: Research Development Foundation
    Inventors: Marc Feldman, Thomas Milner, Tianyi Wang, Jennifer Phipps
  • MEDIUM COMPRISING TRANSFORMING GROWTH FACTOR BETA 1 AND BASIC FIBROBLAST GROWTH FACTOR
    Publication number: 20160312180
    Abstract: The present invention is of methods of establishing and propagating human embryonic stem cell lines using feeder cells-free, xeno-free culture systems and stem cells which are capable of being maintained in an undifferentiated, pluripotent and proliferative state in culture which is free of xeno contaminants and feeder cells.
    Type: Application
    Filed: July 4, 2016
    Publication date: October 27, 2016
    Applicant: Technion Research & Development Foundation Limited
    Inventors: Michal AMIT, Joseph ITSKOVITZ-ELDOR
  • Alpha-hydrogen substituted nitroxyls and derivatives thereof as catalysts
    Patent number: 9475774
    Abstract: Novel alpha-hydrogen substituted nitroxyl compounds and their corresponding oxidized (oxoammonium cations) and reduced (hydroxylamine) forms, and the use of such compounds, inter alia, for oxidation of primary and secondary alcohols to aldehydes and ketones, respectively; resolution of racemic alcohols; desymmetrization of meso-alcohol; as radicals and spin trapping reagents; and as polymerization agents. Processes for preparing the novel nitroxyl/oxoammonium/hydroxylamine compounds from the corresponding amines, and certain novel amine derivatives and their uses. The compounds and amine precursors are useful as ligands for transition metals and as organocatalysts in e.g., aldol reactions.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: October 25, 2016
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Alex M. Szpilman, Michal Amar
  • Methods and compositions relating to improved lentiviral vectors and their applications
    Patent number: 9476062
    Abstract: The present invention provides HIV-derived lentivectors which are safe, highly efficient, and very potent for expressing transgenes for human gene therapy, especially, in human hematopoietic progenitor cells as well as in all other blood cell derivatives. The lentiviral vectors comprise a self-inactivating configuration for biosafety and promoters such as the EF1? promoter as one example. Additional promoters are also described. The vectors can also comprise additional transcription enhancing elements such as the wood chuck hepatitis virus post-transcriptional regulatory element. These vectors therefore provide useful tools for genetic treatments such as inherited and acquired lympho-hematological disorders, gene-therapies for cancers especially the hematological cancers, as well as for the study of hematopoiesis via lentivector-mediated modification of human HSCs.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: October 25, 2016
    Assignee: Research Development Foundation
    Inventors: Didier Trono, Patrick Salmon
  • NOVEL ANTIMICROBIAL AGENTS
    Publication number: 20160303246
    Abstract: A novel class of antimicrobial polymeric agents, which include a plurality of positively charged amino acid residues and at least one omega-amino-fatty acid residue linking therebetween, designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same.
    Type: Application
    Filed: June 20, 2016
    Publication date: October 20, 2016
    Applicant: Technion Research & Development Foundation Limited
    Inventors: Amram MOR, Inna RADZISHEVSKY
  • Immunoreactive protein orthologs of and
    Patent number: RE46254
    Abstract: The present invention concerns gp36 immunoreactive compositions for E. canis and gp 47 immunoreactive compositions for E. chaffeensis. In particular, epitopes for E. canis gp36 and E. chaffeensis gp 47 are disclosed. In certain embodiments, the immunoreactive compositions comprise tandem repeats having carbohydrate moieties.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: December 27, 2016
    Assignee: Research Development Foundation
    Inventors: Jere W. McBride, Christopher K. Doyle